This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.
Frontiers in pharmacology, 14, 1226778
Citation
Feng, Zhen; Tong, Wai Kei; Zhang, Xinyue; Tang, Zhijia. (2023). Cost-effectiveness analysis of once-daily oral semaglutide versus placebo and subcutaneous glucagon-like peptide-1 receptor agonists added to insulin in patients with type 2 diabetes in China.. Frontiers in pharmacology, 14, 1226778. https://doi.org/10.3389/fphar.2023.1226778